OrganOx metra System
Organox Limited · Decision date Jul 8, 2026
What did the FDA decide?
FDA records P200035/S040 as a supplement to PMA P200035, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 8, 2026.
FDA approval order statement
approval to transfer the fabrication of components of the OrganOx metra Retained Unit from Camden Boss Limited to Ortumex Systems Limited
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jul 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P200035/S040
- Regulatory pathway
- PMA supplement
- Applicant
- Organox Limited
- Product code
- QQK
- Decision code
- OK30
- Decision date
- Jul 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.
- Applicant
- Organox Limited
- Product code
- QQK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200035. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200035 · Original PMA
OrganOx metra System
P200035/S027 · Related supplement
OrganOx metra System
P200035/S025 · Related supplement
OrganOx metra System
P200035/S026 · Related supplement
OrganOx metra System
P200035/S028 · Related supplement
OrganOx metra System
P200035/S029 · Related supplement
OrganOx metra System
P200035/S030 · Related supplement
OrganOx metra System
P200035/S031 · Related supplement
OrganOx metra System
P200035/S032 · Related supplement
OrganOx metra System
P200035/S035 · Related supplement
OrganOx metra System
P200035/S036 · Related supplement
OrganOx metra System
P200035/S033 · Related supplement
OrganOx metra System
P200035/S039 · Related supplement
OrganOx metra System
P200035/S040 received
Application receipt date recorded by FDA.
P200035/S037 · Related supplement
OrganOx metra System
P200035/S040 · FDA decision
30-Day Notice
P200035/S041 · Related supplement
OrganOx metra System
P200035/S038 · Related supplement
OrganOx metra System
Timeline entries are records held by MedtechLedger for P200035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
OrganOx metra SystemP200035 | Organox Limited | PMA approval | Dec 9, 2021 | FDA |
OrganOx metra SystemP200035/S027 | Organox Limited | PMA supplement | Jul 18, 2025 | FDA |
OrganOx metra SystemP200035/S025 | Organox Limited | PMA supplement | Aug 20, 2025 | FDA |
OrganOx metra SystemP200035/S026 | Organox Limited | PMA supplement | Aug 22, 2025 | FDA |
OrganOx metra SystemP200035/S028 | Organox Limited | PMA supplement | Aug 28, 2025 | FDA |
OrganOx metra SystemP200035/S029 | Organox Limited | PMA supplement | Sep 8, 2025 | FDA |
OrganOx metra SystemP200035/S030 | Organox Limited | PMA supplement | Sep 19, 2025 | FDA |
OrganOx metra SystemP200035/S031 | Organox Limited | PMA supplement | Dec 17, 2025 | FDA |
OrganOx metra SystemP200035/S032 | Organox Limited | PMA supplement | Mar 16, 2026 | FDA |
OrganOx metra SystemP200035/S035 | Organox Limited | PMA supplement | Mar 30, 2026 | FDA |
OrganOx metra SystemP200035/S036 | Organox Limited | PMA supplement | Apr 10, 2026 | FDA |
OrganOx metra SystemP200035/S033 | Organox Limited | PMA supplement | May 21, 2026 | FDA |
OrganOx metra SystemP200035/S039 | Organox Limited | PMA supplement | Jun 5, 2026 | FDA |
OrganOx metra SystemP200035/S037 | Organox Limited | PMA supplement | Jul 7, 2026 | FDA |
OrganOx metra SystemP200035/S041 | Organox Limited | PMA supplement | Aug 7, 2026 | FDA |
OrganOx metra SystemP200035/S038 | Organox Limited | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code QQK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Organ Care System (OCS) LiverP200031/S013 | TransMedics, Inc. | PMA supplement | May 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Organox Limited
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Oxford Science Park, Magdalen Centre, Robert Robinson Ave., Oxford, OX4 4GA
Sources and methodology
- Original FDA record: P200035/S040
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





